Biognosys has developed a new MRM assay panel for the early prediction of drug toxicity in pre-clinical research studies.
The LiverDig 100 assay panel, which is based on the MRM technology, is suitable for use in various pre-clinical applications including mode of action studies, screening and validation of new drug toxicity biomarkers.
The panel also has the potential to accurately quantify 100 distinct rat liver proteins in a single measurement, according to Biognosys.
Biognosys said the panel is offered for measurements as fee-for-service in its facility and as a product for transfer to any CRO (including GLP-certified) equipped with triple quadrupole mass spectrometers.
The company's first generation MRM assay panel is PlasmaDive for routine laboratory analytics.
